Prescription drug · NDA
Kygevvi NDC 50474-350
doxecitine and doxribtimine · Doxecitine 2 g/1; Doxribtimine 2 g/1 · Powder, For solution · Oral · UCB, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50474-350-30 | 50474035030 | 30 PACKET in 1 CARTON (50474-350-30) / 1 POWDER, FOR SOLUTION in 1 PACKET (50474-350-01)Marketed from Mar 1, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Kygevvi
- Generic name (nonproprietary)
- doxecitine and doxribtimine
- Active ingredients
- Doxecitine — 2 g/1Doxribtimine — 2 g/1
- Dosage form
- Powder, For solution
- Route
- Oral
- Labeler
- UCB, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 219792
- Marketing start
- Listing expires
- Identifiers
- Product ID 50474-350_433f8057-35f8-f7e8-e063-6294a90a3ffdSPL ID 433f8057-35f8-f7e8-e063-6294a90a3ffdSPL set ID 7d5ce670-9314-4fd7-8b0a-1447910dcf9eRxCUI 2737535, 2737541UNII 0W860991D6, VC2W18DGKR
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450474035030followed by a unit qualifier and the quantityPackage 50474-0350-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )
Excerpt only. Read the full label for complete information.